Intraocular pressure response to rimexolone

J. S. Hoop, L. B. Cantor, N. P. Alvi, V. D. Bhavnani

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the incidence of increased intraocular pressure (iOP) in individuals with a history of steroid res lonsiveness when challenged with rimcxolone. Methods: Individuals with a history of increased iOP to either topical or oral corticosteroids were recruited in this ongoing study. Following IRB approval and informed consent 5 subjet ts to date have been challenged with rimexolone l%(VexoI, Alcon Laborato -ies, Inc.). Subjects could have glaucoma, uveitis or no ocular disease but their IOP had to he controlled and no active inflammation could be present. Subjec's could not be on any corticosteroid medication or topical beta-blocker. Following baseline evaluation rimcxolone 1 % was started in one eye for up to 6 week; with iOP assessment every 1 lo 2 weeks. If IOP increased greater than 8mm Hg tne medication was stopped. Results: Intraocular pressure increased 17mm H j and 15 mm Hg following 4 and 6 weeks respectively in two of five subjects when challenged with rimexolone. Conclusions: Despite reports suggesting a reduced risk of steroid responsiveness with rimexolone, significant elevations :>f intraocular pressure may occur.

Original languageEnglish (US)
Pages (from-to)S279
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
StatePublished - Dec 1 1997

Fingerprint

Intraocular Pressure
Adrenal Cortex Hormones
Steroids
Eye Diseases
Research Ethics Committees
Uveitis
Informed Consent
Glaucoma
rimexolone
Inflammation
Incidence

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Intraocular pressure response to rimexolone. / Hoop, J. S.; Cantor, L. B.; Alvi, N. P.; Bhavnani, V. D.

In: Investigative Ophthalmology and Visual Science, Vol. 38, No. 4, 01.12.1997, p. S279.

Research output: Contribution to journalArticle

Hoop, JS, Cantor, LB, Alvi, NP & Bhavnani, VD 1997, 'Intraocular pressure response to rimexolone', Investigative Ophthalmology and Visual Science, vol. 38, no. 4, pp. S279.
Hoop, J. S. ; Cantor, L. B. ; Alvi, N. P. ; Bhavnani, V. D. / Intraocular pressure response to rimexolone. In: Investigative Ophthalmology and Visual Science. 1997 ; Vol. 38, No. 4. pp. S279.
@article{89324fcfa9c04d43ab2b16859d80790a,
title = "Intraocular pressure response to rimexolone",
abstract = "Purpose: To evaluate the incidence of increased intraocular pressure (iOP) in individuals with a history of steroid res lonsiveness when challenged with rimcxolone. Methods: Individuals with a history of increased iOP to either topical or oral corticosteroids were recruited in this ongoing study. Following IRB approval and informed consent 5 subjet ts to date have been challenged with rimexolone l{\%}(VexoI, Alcon Laborato -ies, Inc.). Subjects could have glaucoma, uveitis or no ocular disease but their IOP had to he controlled and no active inflammation could be present. Subjec's could not be on any corticosteroid medication or topical beta-blocker. Following baseline evaluation rimcxolone 1 {\%} was started in one eye for up to 6 week; with iOP assessment every 1 lo 2 weeks. If IOP increased greater than 8mm Hg tne medication was stopped. Results: Intraocular pressure increased 17mm H j and 15 mm Hg following 4 and 6 weeks respectively in two of five subjects when challenged with rimexolone. Conclusions: Despite reports suggesting a reduced risk of steroid responsiveness with rimexolone, significant elevations :>f intraocular pressure may occur.",
author = "Hoop, {J. S.} and Cantor, {L. B.} and Alvi, {N. P.} and Bhavnani, {V. D.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "38",
pages = "S279",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - Intraocular pressure response to rimexolone

AU - Hoop, J. S.

AU - Cantor, L. B.

AU - Alvi, N. P.

AU - Bhavnani, V. D.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose: To evaluate the incidence of increased intraocular pressure (iOP) in individuals with a history of steroid res lonsiveness when challenged with rimcxolone. Methods: Individuals with a history of increased iOP to either topical or oral corticosteroids were recruited in this ongoing study. Following IRB approval and informed consent 5 subjet ts to date have been challenged with rimexolone l%(VexoI, Alcon Laborato -ies, Inc.). Subjects could have glaucoma, uveitis or no ocular disease but their IOP had to he controlled and no active inflammation could be present. Subjec's could not be on any corticosteroid medication or topical beta-blocker. Following baseline evaluation rimcxolone 1 % was started in one eye for up to 6 week; with iOP assessment every 1 lo 2 weeks. If IOP increased greater than 8mm Hg tne medication was stopped. Results: Intraocular pressure increased 17mm H j and 15 mm Hg following 4 and 6 weeks respectively in two of five subjects when challenged with rimexolone. Conclusions: Despite reports suggesting a reduced risk of steroid responsiveness with rimexolone, significant elevations :>f intraocular pressure may occur.

AB - Purpose: To evaluate the incidence of increased intraocular pressure (iOP) in individuals with a history of steroid res lonsiveness when challenged with rimcxolone. Methods: Individuals with a history of increased iOP to either topical or oral corticosteroids were recruited in this ongoing study. Following IRB approval and informed consent 5 subjet ts to date have been challenged with rimexolone l%(VexoI, Alcon Laborato -ies, Inc.). Subjects could have glaucoma, uveitis or no ocular disease but their IOP had to he controlled and no active inflammation could be present. Subjec's could not be on any corticosteroid medication or topical beta-blocker. Following baseline evaluation rimcxolone 1 % was started in one eye for up to 6 week; with iOP assessment every 1 lo 2 weeks. If IOP increased greater than 8mm Hg tne medication was stopped. Results: Intraocular pressure increased 17mm H j and 15 mm Hg following 4 and 6 weeks respectively in two of five subjects when challenged with rimexolone. Conclusions: Despite reports suggesting a reduced risk of steroid responsiveness with rimexolone, significant elevations :>f intraocular pressure may occur.

UR - http://www.scopus.com/inward/record.url?scp=33749133635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749133635&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749133635

VL - 38

SP - S279

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -